Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosis

Affiliations

¹ Johns Hopkins University, Baltimore, MD, USA.
² University of Colorado, Aurora, CO 80045, USA. Electronic address: john.corboy@cuanschutz.edu.

Comment

Ellen M Mowry et al. Lancet Neurol. 2019 Nov.

. 2019 Nov;18(11):983-985.

doi: 10.1016/S1474-4422(19)30333-3. Epub 2019 Sep 3.

¹ Johns Hopkins University, Baltimore, MD, USA.
² University of Colorado, Aurora, CO 80045, USA. Electronic address: john.corboy@cuanschutz.edu.

No abstract available

Comment on

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators. Comi G, et al. Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492651 Clinical Trial.
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators. Cohen JA, et al. Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492652 Clinical Trial.